Physician profile
Norma Wenger
NPI 1427035971
$3,809.26
in general payments reported to CMS, 2019-2025
26 companies · $1,529 in 2025
The $1,529 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2021: $156 · 2022: $502 · 2023: $610 · 2024: $644 · 2025: $1,529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,703 · Education: $79.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,703.07 |
| Education | $79.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $455.30 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $423.24 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $284.93 | 2023-2025 | Acthar, Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $278.29 | 2021-2025 | |
| Nxstage Medical, INC. | $270.66 | 2022 | |
| Glaxosmithkline, LLC. | $259.02 | 2023-2025 | Benlysta |
| Vifor Pharma, INC. | $206.63 | 2019-2025 | Veltassa, Korsuva |
| Novo Nordisk INC | $202.73 | 2025 | Wegovy, Ozempic |
| Amgen INC. | $186.37 | 2019-2025 | Krystexxa, Tavneos |
| Novartis Pharmaceuticals Corporation | $174.21 | 2025 | |
| Travere Therapeutics, INC. | $144.18 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $143.92 | 2022-2024 | Lupkynis |
| Ani Pharmaceuticals, INC. | $135.10 | 2023 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $102.27 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $96.84 | 2019-2024 | Velphoro, Korsuva |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $77.45 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $70.75 | 2024-2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $51.55 | 2019-2025 | Rayaldee |
| Mallinckrodt Enterprises LLC | $45.73 | 2019 | |
| Pfizer INC. | $42.93 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.39 | 2025 | Jardiance |
| Scpharmaceuticals INC. | $28.63 | 2025 | |
| Horizon Therapeutics Plc | $27.60 | 2022 | |
| Baxter Healthcare | $24.78 | 2019 | |
| Sanofi Pasteur INC. | $22.94 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.82 | 2024 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norma Wenger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.